TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

COLY-MYCIN S

COLISTIN SULFATE
Infectious Disease Approved 1962-05-17
1
Indication
--
Phase 3 Trials
63
Years on Market

Details

Status
Prescription
First Approved
1962-05-17
Routes
OTIC, ORAL
Dosage Forms
SUSPENSION/DROPS, SUSPENSION

COLY-MYCIN S Approval History

Loading approval history...

What COLY-MYCIN S Treats

1 indications

COLY-MYCIN S is approved for 1 conditions since its original approval in 1962. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Bacterial Infection
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

COLY-MYCIN S FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Cortisporin ® TC Otic is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.